				<section class="container">
					<p class="boxed blue">ABILIFY<sup>&reg;</sup> (aripiprazole) is indicated for the treatment of schizophrenia in adults.</p>
					<div style="width:80%;margin:0 auto;">
						<h6>Efficacy in adult Schizophrenia</h6>
						<h6 style="margin-top:.2em;font-size:1.3em;">Study design: 4-week Schizophrenia trial<sup>1</sup></h6>
						<img  src="http://placehold.it/784x600">
						<table class="content">
							<caption class="dotted">Symptoms of Schizophrenia Measured by PANSS<sup>&trade;</sup> Total Score</caption>
							<tbody class="dotted">
								<tr>
									<td><strong>Positive Subscale:</strong></td>
									<td><strong>Negative Subscale:</strong></td>
								</tr>
								<tr>
									<td>Hostility</td>
									<td>Emotional withdrawal</td>
								</tr>
								<tr>
									<td>Excitement</td>
									<td>Passive apathetic withdrawal</td>
								</tr>
								<tr>
									<td>Delusions</td>
									<td>Difficulty in abstract thinking</td>
								</tr>
								<tr>
									<td>Suspiciousness/persecution</td>
									<td>Blunted affect</td>
								</tr>
								<tr>
									<td>Hallucinatory behavior</td>
									<td>Lack of spontaneity/flow of conversation</td>
								</tr>
								<tr>
									<td>Conceptual disorganization</td>
									<td>Stereotyped thinking</td>
								</tr>
								<tr>
									<td>Grandiosity</td>
									<td>Poor rapport</td>
								</tr>
							</tbody>
						</table>
						<ul class="content">
							<li>Positive symptoms as measured by PANSS Positive Subscale demonstrated significant improvement at 1 week through endpoint at 4 weeks. (Mean change from baseline [<em>P</em>-values vs placebo at Week 4]: ABILIFY 20 mg -4.9[P<em>P</em>0.001], ABILIFY 30 mg -3.9 [<em>P</em>&lt;0.05], risperidone 6 mg -5.2 [<em>P</em>&lt;0.001], placebo -1.8)</li>
							<li>Negative symptoms as measured by PANSS Negative Subscale demonstrated significant improvement at 1 week through endpoint at 4 weeks. (Mean change from baseline [<em>P</em>-values vs placebo at Week 4]: ABILIFY 20 mg -3.4 [<em>P</em>&lt;0.01], ABILIFY 30 mg -3.4 [<em>P</em>&lt;0.01], risperidone 6 mg -3.1 [<em>P</em>&lt;0.01], placebo -0.8)</li>
						</ul>
						<p><strong>Additional PANSS Negative Subscale Results (LOCF):</strong></p>
						<ul class="content">
							<li>In a 4-week trial (N=414) comparing two fixed doses of ABILIFY 15 or 30 mg to placebo, only 15 mg was superior to placebo in the PANSS Negative Subscale (<em>P</em>=0.006)<sup>2</sup></li>
						</ul>
					</div>
					<h5>Contraindication</h5>
					<p>ABILIFY is contraindicated in patients who have known hypersensitivity reactions to ABILIFY. Reactions have ranged from pruritus/urticaria to anaphylaxis.</p>
					<h5>Warning on Suicidality and Antidepressant Drugs</h5>
					<p>Children, adolescents, and young adults taking antidepressants for Major Depressive Disorder (MDD) and other psychiatric disorders are at increased risk of suicidal thinking and behavior. Please see <a href="#">US FULL PRESCRIBING INFORMATION, including Boxed WARNINGS</a>, and <a href="#">Medication Guide</a> for ABILIFY.</p>
					<div style="width:80%;margin:0 auto;">
						<h6>ABILIFY significantly delayed time to relapse</h6>
						<h6 style="margin-top:.2em;font-size:1.3em;">Study design: 26-week Schizophrenia trial<sup>3</sup></h6>
						<p>Data from a 26-week, double-blind, randomized, placebo-controlled trial (N=310) in adult patients with Schizophrenia who were stabilized on other antipsychotic medication for 3 months or longer and were discontinued from these other medications and then administered ABILIFY 15 mg/day or placebo and observed for relapse for a period of up to 26 weeks.</p>
						<img  src="http://placehold.it/784x600">
					</div>
			
					<?php include '../inc/isi.php'; ?>

					<section class="references container" id="references">
						<p><strong>References:</strong></p>
						<ol class="reference">
							<li>Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. <em>Arch Gen Psychiatry</em>. 2003;60(7):681-690.</li>
							<li>Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.</li>
<em>J Clin Psychiatry</em>. 2002;63(9):763-771.
							<li>Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; for the Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. <em>J Clin Psychiatry</em>. 2003;64(9):1048-1056.</li>
						</ol>
					</section>
				</section>